Aclaris Therapeutics, Inc.
ACRS· Nasdaq
ACRSAclaris Therapeutics, Inc.
Filed Aug 8, 2017 · 10-Q · 39 days after period end · 0001558370-17-006211
| Metric | Q2 2017 | Q2 2016 | Q2 2015 | Q2 2014 |
|---|---|---|---|---|
| Net Income | -$14.84M | -$12.87M | -$2.59M | -$2.23M |
| EPS Diluted | -$0.56 | -$0.62 | -$1.52 | -$1.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
ended Jun 30, 2017 · filed Aug 8, 2017 · 39 d after period end
